Avantor (NYSE:AVTR) Reaches New 52-Week Low – Here’s What Happened

Avantor, Inc. (NYSE:AVTR) shares reached a new 52-week low on Thursday . The company traded as low as $17.14 and last traded at $17.73, with a volume of 7219151 shares. The stock had previously closed at $17.35.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Barclays cut their price target on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. UBS Group reaffirmed a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company cut their price target on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Morgan Stanley cut their price target on Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, Stifel Nicolaus cut their price target on Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.92.

Avantor Price Performance

The stock has a market cap of $12.07 billion, a price-to-earnings ratio of 17.05, a price-to-earnings-growth ratio of 1.60 and a beta of 1.28. The stock has a fifty day simple moving average of $21.16 and a 200-day simple moving average of $23.05. The company has a current ratio of 1.07, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period last year, the company posted $0.22 EPS. As a group, equities research analysts expect that Avantor, Inc. will post 1.06 EPS for the current year.

Institutional Trading of Avantor

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTR. Creative Planning grew its holdings in shares of Avantor by 54.0% during the 3rd quarter. Creative Planning now owns 28,136 shares of the company’s stock worth $728,000 after purchasing an additional 9,866 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Avantor by 414.5% during the 3rd quarter. Blue Trust Inc. now owns 7,547 shares of the company’s stock worth $195,000 after purchasing an additional 6,080 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Avantor during the 3rd quarter worth approximately $255,000. Tandem Capital Management Corp ADV grew its holdings in shares of Avantor by 6.7% during the 3rd quarter. Tandem Capital Management Corp ADV now owns 49,582 shares of the company’s stock worth $1,268,000 after purchasing an additional 3,130 shares in the last quarter. Finally, Louisiana State Employees Retirement System acquired a new stake in shares of Avantor during the 3rd quarter worth approximately $4,874,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.